國產新冠口服藥阿茲夫定擬將開放網售 每瓶售價330元人幣
據《界面新聞》報道,內地多個互聯網平臺已開始、或即將放開銷售兩款新冠口服藥,即輝瑞的奈瑪特韋片/利託那韋片組合包裝(PAXLOVID)和真實生物的阿茲夫定。其中,1藥網方面也確認其旗下互聯網醫院的新冠諮詢門診已開始預售輝瑞的新冠口服抗病毒藥物。
國產新冠口服藥阿茲夫定獨家商業化合作方復星醫藥(02196.HK)(600196.SH)確認,阿茲夫定即將開放網售,阿茲夫定將先在方舟健客APP和京東健康(06618.HK)發熱門診上實現線上處方,開具處方同樣需要持有核酸檢測陽性或者抗原檢測陽性作爲依據,每瓶售價330元人民幣(1mg*35片)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.